---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-301402"
form_type: "8-K"
ticker: "ERAS"
cik: "0001761918"
company_name: "Erasca, Inc."
filed_at: "2022-12-09T23:59:59+00:00"
generated_at: "2026-06-21T06:51:48.551564+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Erasca licenses naporafenib from Novartis for $100M upfront plus milestones up to $280M

## Summary
- Upfront: $20M cash plus ~$80M in Erasca common stock (private placement, 6-mo lock-up).
- Regulatory milestones up to $80M; sales milestones up to $200M; low-single-digit royalties.
- Exclusive worldwide license to develop, manufacture, and commercialize naporafenib.
- Novartis reserves right to use IP for non-clinical research and ongoing trials.
- Company presentation (Exhibit 99.1) provides naporafenib overview.

## SEC filing metadata
- accession: 0001193125-22-301402
- form_type: 8-K
- ticker: ERAS
- cik: 0001761918
- company_name: Erasca, Inc.
- filed_at: 2022-12-09T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 1.01, 3.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1761918/000119312522301402/0001193125-22-301402-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1761918/000119312522301402/d429778d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-301402
- JSON: https://secwatch.observer/filing/0001193125-22-301402.json
- Plain text: https://secwatch.observer/filing/0001193125-22-301402.txt

## Key facts
- Material Agreements
  Erasca, Inc. entered into License Agreement with Novartis Pharma AG valued at $20 million upfront cash payment and approximately $80 million in shares (effective 2022-12-09).
  - Action: entry
  - Agreement: license
  - Counterparty: Novartis Pharma AG
  - Value: $20 million upfront cash payment and approximately $80 million in shares
  - Effective: 2022-12-09
  source text: On December 9, 2022, Erasca, Inc. (the Company) entered into an exclusive license agreement (the License Agreement) with Novartis Pharma AG (Novartis) under which the Company was granted an exclusive, worldwide, royalty-bearing license to certain patent and other intellectual property rights owned or controlled by Novartis to develop, manufacture, use, and commercialize naporafenib in all fields of use.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1761918/000119312522301402/0001193125-22-301402-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.